Literature DB >> 15528957

Topical delivery of retinyl ascorbate co-drug. 2. Comparative skin tissue and keratin binding studies.

K Abdulmajed1, C M Heard, C McGuigan, W J Pugh.   

Abstract

Retinyl ascorbate (RA-AsA), an ester co-drug of vitamins A (RA) and C (AsA), is proposed as a topical antioxidant/cell division regulator for reducing UV-induced generation of free radicals and disrupted dermal cell growth. The efficacy of dermatological agents is influenced by their retention within the skin, which is increased by the interaction with skin components. Keratin is the major protein (approximately 95%) in the skin, and this paper reports the binding of RA-AsA, RA, AsA, retinol, ascorbic acid palmitate and retinol palmitate to three tissues-human callus, pig ear skin and bovine horn keratin. Tissue samples were incubated with solutions of compounds and the uptake measured as the ratio of bound/free compound at equilibrium. Binding to keratin was assessed using delipidised tissue, and was much higher for the polar compounds, suggesting dipolar/H-bonding interaction. Binding strength was ranked as human > porcine > bovine, but there was no distinction for highly lipophilic compounds. The binding characteristic of native tissues was complicated by lipid content of the tissues. There seemed to be a dual effect. The binding of very lipophilic materials increased with lipid content, implying that a substantial amount is dissolved in the lipid matrix. For highly polar AsA, lipid content decreased the binding, suggesting that the lipid reduced the strong polar interactions with skin protein/keratin. 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528957     DOI: 10.1159/000081112

Source DB:  PubMed          Journal:  Skin Pharmacol Physiol        ISSN: 1660-5527            Impact factor:   3.479


  1 in total

1.  The role of corneocytes in skin transport revised--a combined computational and experimental approach.

Authors:  Steffi Hansen; Arne Naegel; Michael Heisig; Gabriel Wittum; Dirk Neumann; Karl-Heinz Kostka; Peter Meiers; Claus-Michael Lehr; Ulrich F Schaefer
Journal:  Pharm Res       Date:  2009-02-25       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.